The emergence of multi-drug resistant (MDR) and rifampicin-resistant TB (RR-TB), in addition to other antimicrobial resistance presents a substantial challenge to global TB control efforts. RR-TB is one of the top 4 globally critical pathogens and ranks seventh among all deaths due to a drug resistant pathogen. Furthermore, the emergence of resistance to Bedaquiline and other new TB drugs is a major concern, as a delay in susceptibility detection exacerbates the transmission of MDR-TB strains within communities. Ensuring universal access to drug susceptibility testing (DST) for all forms of TB is therefore a priority for national TB programs. In this session, presented by Professor Leen Rigouts from the Institute Tropical Medicine in Antwerp, we cover essential concepts on strengthening the quality of culture-based or phenotypic DST to ensure access to reliable, quality-assured DST. Please follow the links here to view the recorded ECHO session and download the presentation slides.